Introduction {#s1}
============

Chronic pain is a serious and growing health concern, with an estimated incidence of approximately one-third of the population of the United States, over 100 million people \[[@R1]\]. This imposes a serious economic cost in addition to the human cost, which has been estimated at US\$ 600 billion in direct and economic costs every year \[[@R1]\]. Moderate to severe cancer and non-cancer chronic pain seriously degrades patient quality of life, and interferes with daily activities \[[@R2]\]. There are multiple drug classes used for the treatment of chronic pain, including non-steroidal anti-inflammatory drugs, tricyclic antidepressants (TCA), gabapentinoids, and finally opioid drugs (morphine, fentanyl, etc.), with progression between and within categories to stronger drugs dependent on patient response and the severity and type of the pain \[[@R3],[@R4]\]. However, TCAs and gabapentinoids only work for 42 to 76 percent of the patient population, often leaving opioid drugs such as morphine and fentanyl the only efficacious treatment option for a large percentage of the patient population \[[@R4]\].

Despite their generally high efficacy, opioids can be ineffective in certain pain types and patient populations, including lowered effectiveness for treating neuropathic pain \[[@R5]\]. In addition, opioids induce a constellation of side effects, incuding dependence and addiction, tolerance, constipation, nausea, respiratory depression, somnolence, and mental clouding \[[@R3],[@R6]\]. These side effects also diminish patient quality of life, decrease compliance, and are particularly problematic in long-term chronic users \[[@R7]\]. These limitations of chronic opioid therapy have spurred drug discovery efforts to develop new analgesic drugs with an improved therapeutic profile.

The first serious attempt to modify the chemical structure of morphine to reduce or eliminate addiction occurred in 1874 with the synthesis of diamorphine. Diamorphine was re-synthesized 23 years later and released by the Bayer company in 1898 under the trade name Heroin as a non-addictive morphine replacement and cough suppressant. As was later discovered, Heroin is more potent and more addictive than morphine, making these initial claims laughable in retrospect. However, this initial attempt with Heroin in many ways is emblematic of all future approaches to create non-addictive opioids, even as our methods greatly improved in sophistication. Today, the vast majority of opioid drugs are derivatives of the morphinan scaffold or re-formulations of previous drugs, while preserving the side-effect liabilities that limit the use of older opioids like morphine \[[@R8]\]. Some drugs have been developed which do not have these liabilities, such as ω-conotoxin, which are effective in treating intractable chronic pain. ω-Conotoxin acts by blocking calcium channels, thus blocking pain neuron conduction. However ω-conotoxin and similar drugs must be administered by the intrathecal route, and have a narrow therapeutic index, which is the difference in doses between that which produces the desired effect (analgesia) and that which produces undesired effects. This limits the use of these drugs to specific inpatient care scenarios \[[@R9]\]. There have been a few recent additions to the market which may buck this trend, as the multi-functional drugs tapentadol and tramadol both have moderate efficacy against pain with reduced addiction and abuse rates; however, these are some of the very few opioid drugs that show such promise \[[@R10]\]. Both drugs are mixed opioid receptor agonists and norepinephrine and/or serotonin reuptake inhibitors.

Clearly, new approaches are needed to overcome this fundamental limitation in the opioid drug discovery field. One such promising approach has taken shape over the last 10 to 15 years with a number of discoveries as to the molecular signaling mechanisms of the mu opioid receptor (MOR), the main target of opioid drugs. It has been shown that different signaling cascades are responsible for different aspects of the overall response, which has allowed us to differentiate analgesic signaling (e.g. Gα~I/O)~from side-effect signaling (e.g. βarrestin2). Combined with other molecular discoveries, including negative feedback systems upregulated during opioid treatment, receptor heterodimerization, and methods to improve the drug-like properties of endogenous opioid peptides, these findings suggest new drug discovery approaches that are fundamentally different from previous target-based strategies. These novel approaches hold the potential to develop the opioid without side effects that we have been pursuing for more than a century.

Topics: Functional Selectivity {#s2}
==============================

The idea of selectively targeting signaling cascades for the treatment of pain began in 1999 with the discovery from the Lefkowitz and Caron labs that βarrestin2 knockout (KO) mice had an enhanced anti-nociceptive response with morphine treatment \[[@R11]\]. This finding was provocative, but of course, patients cannot be treated by genetic KO, and βarrestin2 is a ubiquitous signaling regulator that regulates many G protein-coupled receptors (GPCRs). How could one selectively target βarrestin2 at the MOR?

The answer came from a separate discovery in molecular pharmacology at around the same time called functional selectivity (also "biased agonism" or "ligand-directed signaling") \[[@R12]\]. Functional selectivity is the ability of certain ligands to activate the same receptor but to evoke different signaling cascades, likely through the induction of different receptor conformations \[[@R13]\]. This meant that in principle, a ligand could be designed or discovered, which could activate the MOR, but not recruit βarrestin2, recapitulating the benefits of the KO with a ligand that could be used in patients. Developing βarrestin2 biased ligands has generated intense interest and development in the intervening years, and has been expanded to targets beyond the MOR and chronic pain (see below). In addition, this molecular approach is amenable to targets beyond βarrestin2, and more targets for functionally selective drug discovery likely remain to be found, which is an area of great interest in our lab.

βarrestin2 {#s2a}
----------

As mentioned above, the initial finding in βarrestin2 KO mice was enhanced analgesia in response to morphine \[[@R11]\]. The first author of that paper, Laura Bohn, extended these initial findings in further studies demonstrating that βarrestin2 KO mice had reduced respiratory depression, constipation, dependence, and tolerance \[[@R6],[@R14]\]. This represents an increase in the therapeutic index. One caveat from these studies is that the change in therapeutic index was not observed with high doses of morphine, or with any dose of the full MOR agonists fentanyl, methadone, or oxycodone, suggesting that strong activation of the system could override the effects of the loss of βarrestin2 on opioid side effects. Nonetheless, this improvement in the therapeutic index supported the development of functionally selective MOR agonists with low or no βarrestin2 recruitment. A strong effort from multiple labs led to the identification of multiple MOR biased ligands, including herkinorin \[[@R15],[@R16]\] and TRV130 \[[@R17]\]. Other major development programs are also in progress and will be published soon (L. Bohn, conference presentation), and a large collaborative effort recently resulted in the publication of the MOR biased ligand PZM21 \[[@R18]\]. TRV130 and PZM21 have no appreciable differences in βarrestin2 recruitment or G protein coupling *in vitro*; however, PZM21 induces no tail-flick anti-nociception in mice, while TRV130 does so in rats (both produce anti-nociception in the hot plate assay). This unusual difference suggests that signaling effects beyond βarrestin2 may be involved in the comparative performance of these compounds.

All of these discovered ligands display strong bias against βarrestin2 recruitment (usually no efficacy at all) using widely accepted *in vitro* assays of βarrestin recruitment (DiscoveRx, TANGO, BRET). One of the limitations of this field is that there is no quantitative assay for βarrestin recruitment *in vivo*, making it difficult to evaluate these compounds outside of an artificial *in vitro* system. Indeed, depending on assay conditions, morphine can also display low to no βarrestin2 recruitment, demonstrating the importance of assay context in evaluating ligand bias \[[@R15],[@R19]\]. Nonetheless, these biased compounds have replicated some of the expected findings from the βarrestin2 KO studies. PZM21 was found not to induce conditioned place preference and motor activation in mice, along with reduced (but not eliminated) constipation and no respiratory suppression \[[@R18]\]. TRV130, developed by the pharmaceutical company Trevena, also displayed reduced constipation and respiratory depression in mice \[[@R17],[@R20]\]. TRV130 has advanced to clinical trials, the only βarrestin2 biased agonist to do so, where in small group Phase I trials it showed the potential for enhanced analgesia and reduced nausea \[[@R21],[@R22]\]. In a larger Phase II trial, TRV130 did show potent and efficacious analgesia versus a sub-maximal dose of morphine. However, analysis of the adverse events experienced by the patients, including constipation, showed no apparent differences between TRV130 and morphine \[[@R23]\]. Of note, a fixed dosing regimen for TRV130 was used for these studies; dosing according to patient demand could potentially reduce side effects in comparison with morphine beyond what was seen in this trial. TRV130 has since advanced to Phase III trials, which will hopefully confirm whether or not a βarrestin2 biased ligand can treat pain in patients with reduced side effects. Also of note is that none of the biased ligands tested to date have been able to induce enhanced analgesia in preclinical or clinical testing, as was found in the original βarrestin2 KO paper \[[@R11]\]. Overall, there are some caveats and limitations to βarrestin2 as a drug discovery target, including the lack of a structure-activity relationship (SAR) for arrestin bias \[[@R18]\]. However, these are early days, and there is a great deal of excitement for the potential of this type of drug discovery.

Beyond the MOR, other receptors have also been studied for βarrestin2 biased signaling and drug discovery. Work by Chavkin and colleagues suggested that βarrestin2 mediates dysphoria and aversion seen with kappa opioid receptor (KOR) activation, and that a ligand biased against βarrestin2 could cause analgesia without dysphoria and aversion, and without typical MOR side effects \[[@R24],[@R25]\]. A number of ligands biased against βarrestin2 have been found for the KOR, including 6'-guanidinonaltrindole, RB-64, and others \[[@R26]-[@R32]\]. RB-64 was particularly interesting, as it was shown to induce anti-nociception without the KOR side effects of anhedonia and motor dysfunction, while still causing conditioned place aversion \[[@R29]\]. These initial results are promising, but do suggest that targeting the KOR with a biased ligand may still cause aversion -- more research is needed with different biased ligands to determine the future of the KOR as a target for functionally selective drug discovery. Other receptors are also being investigated for functionally selective drug discovery for conditions other than pain, including the dopamine receptors \[[@R33]-[@R36]\], ghrelin receptor \[[@R37]\], and others. Interestingly, for some of these systems, arrestin signaling is beneficial rather than detrimental, leading to an effort to find ligands biased for βarrestin2 \[[@R33]\].

Other Signaling Targets for Functionally Selective Drug Discovery {#s2b}
-----------------------------------------------------------------

βarrestin2 has generated an intense level of interest, but there is every reason to believe that the same approach for functionally selective drug discovery can be applied to other signaling targets, and perhaps to even greater effect. While not many such targets have been identified, efforts by our lab and others to identify new signaling regulators of the MOR may provide more such targets in the future. We discuss a few known potential targets below.

It has been shown that chronic opioid administration results in a cellular response defined by increased adenylyl cyclase (AC) activity, termed AC superactivation. AC superactivation has been proposed to be a contributing factor to opioid-induced tolerance and dependence, suggesting that this mechanism should be targeted by functionally selective drug discovery to potentially reduce these side effects \[[@R38],[@R39]\]. The protein kinase Raf-1, a partner in the Raf/MEK/ERK cascade, has been implicated in adenylyl cyclase superactivation at both the MOR and delta (DOR) opioid receptors *in vitro* \[[@R40],[@R41]\]. It was later shown that knockdown of Raf-1 via siRNA attenuated both morphine-induced sensitization and tolerance *in vivo*, as well as thermal hyperalgesia -- in which previously non-painful stimuli become painful \[[@R42],[@R43]\]. Although MOR regulation involves a complex network of proteins (reviewed in \[[@R44]\]) and there is currently no literature on biased ligands with respect to Raf-1, identifying ligands that do or do not induce adenylyl cyclase activation via Raf-1 will aid in novel biased ligand development. An important caveat is that Raf-1 was shown to be AC subtype-dependent, superactivating AC V/VI; these subtypes may not be the most relevant AC subtypes to dependence and withdrawal *in vivo*.

The termination of MOR signaling is regulated in part by the slow GTPase activity of the Gα subunit, where GTP hydrolysis deactivates the G protein and allows for subsequent reactivation. Additionally, Regulators of G Protein Signaling (RGS) proteins act as GTPase accelerating proteins (GAP), enhancing the rate of GTP hydrolysis up to 100-fold \[[@R45]\]. These proteins thus act as negative regulators of GPCR signaling, and have been suggested to modulate the receptor response to opioids and other drugs of abuse \[[@R46]\].

There are more than 20 RGS proteins, and at least 11 have been implicated in MOR signaling *in vitro* and *in vivo* \[[@R45]\], although they appear to modulate MOR signaling in a variety of ways. For example, one study observed a decrease in morphine anti-nociception after knockdown of RGS2 and RGS3, but an increase after knockdown of RGS4, RGS7, RGS9, RGS12, RGS14, and RGS16, most significantly with RGS9 \[[@R47]\]. Interestingly, these RGS proteins appear to have selectivity in the GPCRs they modulate, as it was shown in SH-SY5Y cells that RGS19 selectively modulates MOR signaling but not DOR or the Nociceptin Receptor (NOP), and that RGS4 selectively modulates DOR signaling \[[@R48],[@R49]\]. However, this appears to be system-dependent, because in other heterologous systems, RGS19 has differing effects on MOR, DOR, and NOP signaling. Lastly, some ligand-specific regulation by RGS proteins has been noted \[[@R50]\]. In this case, expression of an RGS-insensitive Gα~o~ protein induced an increase in potency for the full efficacy agonist DAMGO, but increased both the potency and efficacy for the partial agonist morphine \[[@R50]\]. The diverse modulation RGS proteins exhibit, along with their suggested selectivity for receptors and ligands, make them ideal targets for biased compounds.

Direct Modulation of Downstream Signal Transduction {#s3}
===================================================

Designing functionally selective ligands is advantageous for several reasons, including that they impart the ability to modulate ubiquitously expressed signaling regulators only at a receptor target of interest. This can potentially reduce off-target effects as compared to targeting the signaling regulator itself. However, it is not always possible or desirable to pursue this approach. For instance, a signaling regulator could modulate signal transduction of a target cascade without being directly in the cascade in a way amenable to functionally selective drug discovery. Or, a target could be in the direct cascade, but for technical or other reasons, a functionally selective ligand cannot be found. In these cases, we may still be able to take advantage of the known signal transduction cascades in chronic pain by directly targeting signaling regulators with activators or inhibitors.

One such potential target is Heat shock protein 90 (Hsp90). Hsp90 is a chaperone protein, which is required for activation and stabilization of a variety of proteins \[[@R51]\]. It also has the ablity to modulate intracellular signal transduction molecules, including numerous kinases \[[@R51],[@R52]\]. Hsp90 has been used as a target for anti-cancer drug discovery for over two decades. Compounds targeting Hsp90 can disrupt the activity of oncogenesis-related receptors, kinases and transcription factors \[[@R53]\]. A few previous studies reported that Hsp90 promotes diabetes-induced hypoalgesia and inflammation-induced allodynia, suggesting that Hsp90 is involved in regulating pain \[[@R54]-[@R56]\]. However, there have been only two studies conducted to investigate the role of Hsp90 specifically in MOR signal transduction and opioid response. Koshimizu et al. demonstrated that Hsp90 inhibition reduces adenylyl cyclase superactivation, a cellular marker of dependence \[[@R57]\]. A paper by the Devi group found that Hsp90 is upregulated by chronic morphine treatment in the pre-synaptic terminal, and that administration of the Hsp90 inhibitor geldanamycin in the periphery immediately prior to naloxone-precipitated withdrawal reduces the somatic signs of dependence and withdrawal \[[@R58]\]. This limited evidence from the literature does suggest that Hsp90 has a role in regulating pain, MOR signal transduction, and opioid behavioral responses. In our own work, we demonstrate that chronic Hsp90 inhibition worsens the opioid therapeutic index by decreasing tail flick and paw withdrawal anti-nociception, and increasing morphine-induced dependence and withdrawal (unpublished data, not shown). Taken together, this data suggets that Hsp90 modulators should be investigated for opioid co-therapy to improve the opioid therapeutic index.

In signaling kinases, previous studies have demonstrated that the activation of ERK1/2 and JNK MAPKs is associated with opioid-induced tolerance \[[@R59]\], dependence \[[@R60]\], hyperalgesia and allodynia \[[@R61],[@R62]\], and constipation \[[@R63]\]. Similar studies also suggest that p38 MAPK is a key player in KOR-induced side effects, such as the aversive properties of stress and dysphoric behaviors \[[@R64]-[@R66]\]. Co-treatment with MOR and KOR agonists with inhibitors to ERK, JNK, or p38 may be a potential strategy to maximize the activity of MOR and KOR agonists without inducing opioid side effects. One caveat, however, is that these signaling kinases are broadly expressed and involved in many biological processes, which increases the risk of non-opioid side effects from targeting these molecules. Strategies such as protein-protein interaction disruptors or targeted brain delivery of inhibitors could impart more selectivity to targeting these molecules and reduce potential side effects.

Several reports have also suggested that opioids can bind to other receptors and activate the intracellular signaling pathways associated with these receptors. Watkins and colleagues have demonstrated that morphine and its metabolite can activate the toll-like receptor 4 (TLR4), which may be involved in the development of hyperalgesia, dependence, and allodynia \[[@R67]-[@R69]\]. Activating TLR4 signaling also induces the production of pro-inflammatory cytokines and prostaglandin E2, which can reduce the analgesic activity of opioids \[[@R70],[@R71]\]. Selfridge et al. demonstrated that a naltrexone-based compound inhibited TLR4 activation, and increased and prolonged morphine analgesia \[[@R72]\]. These findings indicate that TLR4 and its downstream signaling mediators could also be targeted for direct inhibition to improve the opioid therapeutic index. The possibilities suggested here are not exhaustive, and many potential signaling regulators could be targeted by this approach as our knowledge of opioid signal transduction grows.

Multi-Functional Compounds {#s4}
==========================

Over the past few decades, much basic science knowledge has been generated demonstrating how opioid-induced side effects are expressed. One major theme is that as the MOR system is chronically stimulated, other negative feedback systems are also upregulated to compensate. Several of these feedback systems have been identified, and shown to help drive opioid side effects. This has led to the idea of multi-functional compounds that target the MOR and a negative feedback system, to both activate the MOR to produce analgesia and antagonize the negative feedback system to reduce side effects. This is an example of basic science knowledge driving rational drug design from the beginning, rather than a blind target-based approach. Tapentadol and tramadol are examples of multi-functional drugs that have reached the market with evidence for reduced addiction liability, while a new generation of multi-functional drugs is in pre-clinical and early clinical development \[[@R10]\]. Both tapentadol and tramadol are mixed MOR agonists and norepineprhine and/or serotonin reuptake inhibitors.

Cholecystokinin {#s4a}
---------------

Porreca and colleagues found in several seminal studies that cholecystokinin(CCK)-containing neurons are a MOR negative feedback loop upregulated in the rostroventral medulla \[[@R5],[@R13],[@R73]-[@R79]\]. They found that CCK may drive the seemingly paradoxical phenomenon of opioid-induced hyperalgesia (OIH), promote neuropathic pain, drive opioid-induced reward, reduce opioid analgesic potency, and similar effects. Notably, treatment with a CCK antagonist could reverse some of these effects, suggesting that a multi-functional MOR agonist/CCK antagonist could be a beneficial therapeutic tool (i.e. \[[@R77]\]). This led to a program of drug development to make peptide and small molecule MOR agonist/CCK antagonist compounds, which have shown potent anti-nociception in chronic and acute pain models in mice and rats, along with some reduced side effects, notably reward \[[@R80]-[@R87]\] (F. Porreca, unpublished data).

Delta Opioid Receptor {#s4b}
---------------------

The DOR has also been found to drive opioid-mediated side effects. Treatment with the DOR selective antagonist naltrindole, DOR antisense DNA, or DOR KO all reduced opioid-mediated tolerance, as well as other side effects, including dependence (depending on individual study) \[[@R88]-[@R90]\]. As above, this suggested the idea of a multi-functional MOR agonist/DOR antagonist to recapitulate these benefits. This has led to a peptide, peptidomimetic, and small molecule discovery and development effort by several labs, resulting in the production of molecules with the desired multi-functional properties \[[@R91]-[@R96]\]. These molecules generally did not produce tolerance, dependence, or conditioned place preference (i.e. reward) in rodents, while still producing potent and efficacious anti-nociception, validating the approach. These molecules will continue preclinical development, and will hopefully reach clinical testing soon.

One paradoxical finding in this field is that both MOR agonist/DOR antagonists as well as multi-functional MOR and DOR agonists are found to be beneficial. The MOR/DOR agonist MMP-2200 has been found to produce anti-nociception with reduced tolerance, dependence, and self-administration, suggesting lower abuse liability \[[@R97]-[@R99]\]. At this point, the mechanisms behind this seeming paradox are completely unknown, leaving us with the unusual situation that both multi-functional MOR agonist/DOR antagonist and MOR/DOR agonist drugs are valid targets for drug discovery to reduce opioid side effects.

Neurokinin Receptors {#s4c}
--------------------

Pioneering work by Todd Vanderah and colleagues has strongly suggested that the neurokinin 1 (NK1) and, possibly, NK3 receptors drive opioid-mediated reward in the ventral tegmental area, as well as OIH and tolerance in other circuits (T. Vanderah, unpublished data) \[[@R100],[@R101]\]. As above, this has suggested multi-functional MOR agonist/NK1 antagonists. A series of peptide ligands with this profile has been created, which shows anti-nociception with reduced tolerance and reward \[[@R102]-[@R107]\]. The further challenge for this target will be to make the initial peptide ligands druggable, by creating peptidomimetics or small molecules, or perhaps through novel peptide modifications such as glycosylation (see below). This will permit further development and clinical testing to truly validate the promise of this approach.

Beyond these initial targets, there are many potential targets for a multi-functional drug discovery approach, some of which remain to be discovered. Others which have been suggested include MOR agonist/KOR antagonist (YS. Lee, unpublished data), and MOR agonist/Cannabinoid1 or 2 agonist (T. Vanderah, unpublished data). Any system that is found to synergize with the opioid system or drive its side effects is amenable to this type of approach.

Opioid Receptor Heterodimers {#s5}
============================

The past decade has seen significant *in vitro* evidence indicating that GPCRs form functionally distinct heterodimer structures, with distinct biochemical and pharmacological properties compared to their homodimer or monomer counterparts. Heterodimer targets for pain most frequently consist of one opioid protomer (MOR or DOR), and a second GPCR protomer with a role in pain signal transduction, such as DOR, KOR \[[@R108]\], or CCR \[[@R109]\], among others. Conceptually, GPCR heterodimer ligands can be classified in two ways: 1) A single molecule consisting of two pharmacophores, separated by a linker of appropriate length, promoting simultaneous binding to both active sites, or 2) a single molecule that prefers one (or both) protomer(s) when in the heterodimer conformation. These distinctions are not necessarily mutually exclusive, but provide a useful tool for considering heterodimer studies involving pain and potential future drug discovery.

MOR-DOR Heterodimers {#s5a}
--------------------

BRET studies found that the MOR forms heterodimers with DOR (MDOR) along with heterodimers between DOR and KOR (DKOR) *in vitro* \[[@R108]\]. Co-expression of MOR and DOR generates a novel pharmacological target with distinct receptor binding properties, indicating a unique receptor conformation \[[@R110]\] and unique signaling scaffolds relative to MOR or DOR homomers \[[@R111]\]. *In vivo* studies using mice co-expressing mCherry-MOR and GFP-DOR found each receptor throughout important regulatory pain regions such as the medulla, periaqueductal grey, and pons in brain \[[@R112]\], indicating that MDOR *could* be important in these regions. Their model was validated using pull-downs in the hippocampus to confirm that co-expression can lead to heterodimer complexes \[[@R112]\].

MDOR is potentially extensively expressed in the brain, with approximately 40 percent of neurons that express GFP-DOR co-expressing mCherry-MOR \[[@R112]\]. The functional consequences of MDOR remain difficult to dissect, although initial studies indicate that targeting MDOR may lead to improved analgesics with reduced side effects such as tolerance. A MDOR-specific antibody was developed to label and quantify MDOR in brain tissue \[[@R113]\], uncovering MDOR up-regulation after chronic morphine treatment in the medulla and other pain regulatory brain regions, and suggesting a potential role in tolerance requiring further investigation. Another group used the first transmembrane region of MOR (MOR^TM1^) \[[@R114]\] to disrupt the MDOR heterodimer, which enhanced morphine analgesia and reduced anti-nociceptive tolerance. Together, these studies suggest that MDOR disruption may enhance analgesia and reduce tolerance.

Agonists with modest MDOR selectivity suggest that activating MDOR may be an important therapeutic target. Screening of a small molecule library revealed a modestly selective agonist, CYM51010, with 1:4:6 MDOR:MOR:DOR selectivity and efficacy in cells co-expressing MDOR versus MOR or DOR in a βarrestin2 recruitment assay \[[@R115]\]. The Portoghese group developed bivalent ligands containing a MOR agonist, oxymorphone, linked to the DOR antagonist naltrindole, with enhanced analgesia and reduced tolerance relative to morphine. Potency increased and tolerance decreased in a length-dependent manner \[[@R116]\], showing that linker lengths of 21 (MDAN-21) atoms were optimal. Follow-up studies revealed that MDAN-21 reduced MDOR internalization relative to mixed or single treatment with the pharmacophores, suggesting that reduced MDOR internalization may be the mechanism for reduced *in vivo* tolerance \[[@R117]\]. While internalization for CYM51010 has not been reported, the contrast of agonist activity at MOR and DOR compared to agonist at MOR and antagonist at DOR -- not to mention the disruption studies -- make the mechanism of MDOR-mediated effects unclear, even if these ligands offer promising results for analgesic development.

KOR-DOR Heterodimers {#s5b}
--------------------

Another opioid heterodimer target for drug discovery is KOR and DOR (KDOR) \[[@R118]\]. A screening method using a chimeric Gα and intracellular Ca^2+^ in cells expressing DOR, KOR, or KDOR identified 6'GNTI as a five-fold selective ligand in cells co-expressing KOR and DOR, relative to KOR. Selective KDOR activation by 6'GNTI was further suggested when it was found that 6'GNTI only induces anti-nociception when injected into the spinal cord, not brain, while non-selective KOR agonists like U50,488 induce anti-nociception in both locations \[[@R119]\]. Paw withdrawal latency of 6'GNTI was reversed by either a peripherally injected DOR (naltrindole) antagonist or a KOR antagonist (nor-BNI) in models of inflammatory peripheral pain \[[@R120]\]. However, the *in vitro* system to characterize these compounds is fairly artificial, as it requires co-expression of a mutant Gq chimera protein, whereas opioids classically signal through Gα~i/o~. The spinal-mediated analgesia of 6'-GNTI is also dependent on bias against βarrestin signaling -- that is, activation of G protein, but not βarrestin, at KOR was important for analgesia \[[@R111],[@R119]\]. Synthetic analogues of 6'GNTI for KDOR selective agonists identified N-2′-Indolylnaltrexamine (INTA) as a candidate \[[@R121]\]. Interestingly, HEK293 cells co-expressing KOR and DOR did not result in significant βarrestin2 recruitment upon INTA treatment, suggesting that functional selectivity and heterodimer-mediated activity are intertwined. However, the low-level βarrestin2 recruitment by any ligand in their system suggests that these results could arise from experimental sensitivity. Regardless of the mechanism, INTA did not show conditioned place preference, suggesting a lack of reward after chronic treatment, as would be predicted for KOR biased agonists.

MOR-CCR5 Heterodimers {#s5c}
---------------------

In CHO cells co-expressing MOR and CCR5 receptors, heterodimerization was found as assessed by co-immunoprecipitation studies. One component of morphine tolerance in inflammatory pain states is from chemokine release and hyperalgesia. Interestingly, the response to DAMGO (MOR agonist) or RANTES (CCR5 agonist) exhibited cross-desensitization, suggesting that these receptor systems interact \[[@R109]\]. DAMGO pretreatment reduced RANTES (CCL5)-promoted \[^35^S\]GTPγS coupling, while RANTES pre-incubation significantly reduced DAMGO-induced GTPγS coupling in co-expressing cells, suggesting a heterodimer. In this light, a bivalent ligand consisting of a MOR agonist and CCR5 antagonist was designed to study the effects of MOR-CCR5 heterodimers \[[@R122]\] on analgesia in inflammatory pain models. MC22 -- a compound with a 22-atom spacer -- improved anti-nociceptive potency 2000-fold over morphine in mice treated with lipopolysaccharide -- a common model for inflammatory pain. While these papers did not include molecular pharmacology characterization of the compounds, the 22-atom linker length was significantly more potent *in vivo* than other linker lengths. Furthermore, relative to morphine and other linker lengths, MC22 showed a significant reduction in anti-nociceptive tolerance in chronic pain models. Due to the absence of molecular characterization, it is unclear how this molecule affects MOR-CCR5 signaling, but this remains a promising target for drug discovery.

Taken together, bivalent and heterodimer selective compounds at various opioid targets provide intriguing alternatives to minimize tolerance profiles and treat specific types of pain, such as neuropathic pain (MOR-CCR5). However, major limitations of the heteromer-mediated mechanism leading to reduced tolerance include: 1) The *in vitro* selectivity of these compounds is typically under 100-fold when molecular characterization is performed, and 2) many ligands -- such as with MOR-CCR5 or MOR-DOR -- connect a MOR agonist to an antagonist, and it remains unclear how the simultaneous occupation of an agonist and antagonist affects heterodimer signaling. Thus, further studies utilizing pharmacological tools that act as heterodimer antagonists or heterodimer agonists are required. Nonetheless, the therapeutic potential of MOR-DOR and MOR-CCR5 to develop molecules with reduced tolerance and side effect profiles is promising.

Making Endogenous Opioid Peptides Druggable {#s6}
===========================================

Endogenous opioid peptides such as endorphins, enkephalins, dynorphins, and endomorphins have been in focus as potential analgesic drug candidates for many years \[[@R123],[@R124]\]. Although their *in vivo* efficacies are comparable to those of the alkaloid opiate derivatives in animal models of pain, and their side effect profiles are generally superior to small molecule drugs, the direct use of endogenous opioid peptides as analgesic drugs is still limited by their general lack of receptor selectivity (not true for all -- especially endomorphins or targeting the KOR with dynorphins), short *in vivo* half-life, poor blood-brain barrier penetration, and poor bioavailability. To improve these pharmacological properties, several structural modification-based strategies have been developed and introduced in recent years \[[@R123],[@R125]\]. We will briefly discuss these approaches below, placing emphasis on the advanced methodologies that may possibly result in bioavailable, potent, opioid peptide-based drug candidates in the near future.

Glycosylation {#s6a}
-------------

To increase bioavailability and blood-brain barrier permeability of endogenous opioid peptides, glycosylation of the peptide backbone by incorporation of glycosylated amino acids or sugar-amino acid moieties has been pursued. This is an attractive strategy, since glycosylation is one of the least toxic and most common post-translational modifications *in vivo*. This chemical intervention, using various types of carbohydrates, not only facilitates blood-brain barrier permeability of the target peptide *in vivo*, but occasionally also confers higher potency and proteolytic stability to the peptides \[[@R126],[@R127]\]. This strategy has been successfully used for the generation of bioavailable β-endorphin, enkephalin, and endomorphin derivatives that are systemically stable, cross the blood-brain barrier, and have potent anti-nociception with often reduced side effects \[[@R127]-[@R129]\]. 

Cyclization {#s6b}
-----------

Cyclization of the peptide backbone of opioid peptides, a typical conformational constraint, is a widely used approach to enhance receptor selectivity and proteolytic stability, reduce off-target toxicity, and modulate binding activity. Since peptide analogs with appropriate conformational constraints tend to adopt specific conformations required for interaction at one receptor type but not another, conformational constraint has proved to be an extremely useful tool to dissect peptide binding characteristics. These backbone modifications include amide bond formation, disulfide-, hydrazine-, carbonyl- and amine bridges, or incorporation of cyclic amino acids or side chain conformational constraints. This can lead to very selective and potent agonist or antagonist ligands for all three types of opioid receptors \[[@R130]-[@R134]\]. Notably, a recent series of cyclized endomorphin derivatives from the Zadina group has shown great promise, with *in vivo* bioavailability, anti-nociception, and greatly reduced reward, abuse liability, and several other typical opioid induced side effects \[[@R135]\].

Other Modifications {#s6c}
-------------------

Another structural modification is the N- or C-terminal conjugation of opioid peptides with lipids or incorporation of lipo-amino acids in the peptide sequence. This confers an amphipathic character to the opioid peptides which promotes interaction between the ligand and the lipid bilayer of the cell membrane, and possibly increases proteolytic stability and blood-brain barrier permeability \[[@R129],[@R136],[@R137]\].

Alternatively, opioid peptides can be packed into self-assembling monolayer vesicles or peptide-glutathione PEGylated-liposome nanobodies. These are attractive drug formulation approaches that enhance peripheral peptide transport and targeted delivery of opioid cargo into the central nervous system. Some advantages of this strategy are that the release of the encapsulated peptide can be strictly regulated, and the peptide is quasi-protected from proteolytic enzymes while it resides within the vesicle or nanobody. This approach has been widely used to target a variety of central nervous disorders with drugs that cannot normally go through the tightly closed blood-brain barrier \[[@R138]-[@R140]\].

Conclusions and Outlook {#s7}
=======================

Historically, opioids are among the few efficacious options for the treatment of moderate to severe chronic pain, but are limited by significant side effects. More than a century of drug discovery and development has failed to generate a broadly applicable, high-efficacy opioid or other analgesic drug without these basic side effects. However, new findings in the molecular signaling of the MOR have suggested new approaches. As we determine which signaling cascades are responsible for which part of the response, those cascades can be targeted using functionally selective drug discovery, as for βarrestin2, or the molecules can be directly targeted using activators or inhibitors. Separately, multi-functional ligands can also be designed that will activate the MOR to promote analgesia, but antagonize other receptor systems that are upregulated during chronic opioid treatment and drive many side effects, including tolerance, dependence, and addiction. Opioid receptor heterodimers are also relatively new and attractive targets, but are very limited at this point by a lack of specific pharmacological tools. Lastly, endogenous peptide ligands, which are potent with few side effects but are poor drug candidates, may be chemically modified to make them stable and available to the brain for pain treatment. These approaches are summarized in [Figure 1](#F1){ref-type="fig"}.

All of these novel approaches are extremely promising, and may provide a way forward to break the barriers limiting pain drug discovery. However, by far the greatest limitation is that most of these approaches have generated molecules that have only been tested preclinically, in animal models. The biased ligand TRV130 and the multi-functional opioids tapentadol and tramadol are the only real compounds from these approaches that are in clinical testing or approved for human use. The coming years will provide a wealth of information as to the feasibility and translatability of these new approaches to human patients, as these drugs enter clinical trial testing. 

Another potential limitation is that the targets for some of these approaches, particularly functional selectivity, are limited. Extensive additional basic science work is needed to flesh out the signal transduction mechanisms underlying the MOR, and the neural networks and interactions between the MOR and other receptor systems. This basic science exploration will provide the foundation for future development of these approaches to drug discovery and guarantee their future growth, maximizing our chances of successful translation.

Overall, however, the impact of these new approaches is difficult to understate. The need for new analgesic drugs without side effects, particularly addiction, is very pressing, both medically and socially. Drug overdose deaths with opioids have been steadily rising, and the United States now consumes 80 percent of the world's opioid supply. The needs of pain patients are starting to be pitted against the need to control an emerging addiction and overdose epidemic. The invention of an analgesic without side effects, using these new approaches or any other, is crucially needed to avoid this clash where the patients are likely to be the victims.

JS has performed contract research work for Depomed Inc. and Stealth Peptides, which are pharmaceutical companies developing pain drugs. However, none of the molecules or strategies utilized by either company are included in this review.

MOR, KOR, DOR

:   Mu, Kappa, Delta Opioid Receptor

NOP

:   Nociceptin Receptor

TCA

:   tricyclic antidepressants

GPCR

:   G Protein Coupled Receptor

SAR

:   Structure-Activity Relationship

AC

:   adenylyl cyclase

RGS

:   Regulators of G Protein Signaling

GAP

:   GTPase Activating Protein

Hsp90

:   Heat shock protein 90

TLR4

:   Toll-like Receptor 4

CCK

:   cholecystokinin

NK

:   neurokinin

![**Summary of Molecular Strategies for Improved Opioid Drug Discovery**. Opioid drugs such as morphine and fentanyl activate the MOR, which in turns activates signal transduction cascades. These cascades include factors such as βarrestin2, and drive both analgesia and side effects. At the same time, MOR activation leads to activation of negative feedback receptor systems including CCK, which in turn drive the induction of opioid side effects. This process can be targeted by 1) biased ligands which activate the MOR while blocking or not activating negative signal transduction factors downstream such as βarrestin2; 2) signaling modulators which directly target intracellular signaling molecules to activate or inhibit and improve the opioid response; 3) multi-functional drugs which simultaneously activate the MOR to drive analgesia while blocking negative feedback receptor systems to reduce side effects; and 4) druggable endogenous opioid peptides which have a better activation profile than small molecule drugs like morphine.](yjbm_90_1_97_g01){#F1}
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